Blood, human or animal, antisera, other blood fractions and immunological products: malaria diagnostic test kits

In 2024, blood, human or animal, antisera, other blood fractions and immunological products: malaria diagnostic test kits trade exhibited significant decline, with global flows reaching $580,947,683 and a three-year compound annual growth rate of +9.7% (five-year: +11.4%). The all-time peak of $62,927,793,251 was recorded in 2011; the current level is 99% below that high-water mark.

Over the 30-year observation window (1995–2024), 76% of years recorded positive growth, indicating a predominantly expanding market. Trend momentum is steady (+3.0% acceleration).

The supply side is moderately concentrated (Herfindahl-Hirschman Index 0.167). The three largest exporters — Switzerland ($1.5B), Belgium ($196.4M), and Austria ($188.5M) — collectively dominate supply flows. The leading exporter has grown at +59.5% over the last three years.

On the demand side, importer concentration is diversified (HHI 0.114). The three largest import markets are Germany ($129.1M), Belgium ($119.2M), and Netherlands ($74.3M). The largest importing market sources from 36 different supplying countries.

The dominant trade corridor is Belgium → Germany at $120.9M, representing 93.7% of the importer's total demand.

The volatility score for blood, human or animal, antisera, other blood fractions and immunological products: malaria diagnostic test kits is 15 out of 100, classified as low. Trade flows are relatively stable compared to other HS6 products, suggesting mature supply chains and predictable demand.

For market entrants, contracting demand signals caution before committing resources. A moderately concentrated market rewards differentiated positioning and strategic partner selection.

Data confidence is rated "High" based on reporting coverage and consistency across OECD member and partner countries.